Author Affiliations: Department of Ophthalmology and Visual Sciences, The Hospital for Sick Children, Toronto, Ontario, Canada (Drs Mireskandari and Tehrani); and Moorfields Eye Hospital, NHS Trust, London, England (Dr Adams).
In 2011, a landmark article was published that could change the way retinopathy of prematurity (ROP) is treated.1 The Bevacizumab Eliminates the Angiogenic Threat of Retinopathy of Prematurity (BEAT-ROP) trial concluded that intravitreal injection of bevacizumab, 0.625 mg in 0.025 mL, had a beneficial effect compared with laser photocoagulation for zone 1, stage 3+ ROP.1However, their end point for recurrence of disease was only 54 weeks' postmenstrual age (PMA). Previously, Moshfeghi and Berrocal2 estimated that 47.7% of recurrences would have occurred after the 54 weeks' PMA reported in the BEAT-ROP study as the primary end point for treatment success. In this journal, Hu et al3 described their clinical experience with recurrence of ROP following intravitreal injection of bevacizumab, adding further evidence that 54 weeks' PMA is not a sufficient end point for observation.
Mireskandari K, Adams GGW, Tehrani NN. Recurrence of Retinopathy of Prematurity Following Bevacizumab Monotherapy: Is It Only the Tip of the Iceberg?. JAMA Ophthalmol. 2013;131(4):544-545. doi:10.1001/jamaophthalmol.2013.711